- Home
- SHOT vs RNXT Comparison
SHOT vs RNXT Comparison
Compare SHOT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- RNXT
- Stock Information
- Founded
- SHOT 2018
- RNXT 2012
- Country
- SHOT United States
- RNXT United States
- Employees
- SHOT N/A
- RNXT N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- RNXT Health Care
- Exchange
- SHOT Nasdaq
- RNXT Nasdaq
- Market Cap
- SHOT 31.4M
- RNXT 31.6M
- IPO Year
- SHOT 2020
- RNXT 2021
- Fundamental
- Price
- SHOT $0.42
- RNXT $1.03
- Analyst Decision
- SHOT
- RNXT Strong Buy
- Analyst Count
- SHOT 0
- RNXT 1
- Target Price
- SHOT N/A
- RNXT $9.00
- AVG Volume (30 Days)
- SHOT 583.2K
- RNXT 218.8K
- Earning Date
- SHOT 03-31-2025
- RNXT 03-31-2025
- Dividend Yield
- SHOT N/A
- RNXT N/A
- EPS Growth
- SHOT N/A
- RNXT N/A
- EPS
- SHOT N/A
- RNXT N/A
- Revenue
- SHOT $652,495.00
- RNXT N/A
- Revenue This Year
- SHOT N/A
- RNXT N/A
- Revenue Next Year
- SHOT N/A
- RNXT N/A
- P/E Ratio
- SHOT N/A
- RNXT N/A
- Revenue Growth
- SHOT 68.01
- RNXT N/A
- 52 Week Low
- SHOT $0.42
- RNXT $0.77
- 52 Week High
- SHOT $2.89
- RNXT $1.86
- Technical
- Relative Strength Index (RSI)
- SHOT 33.14
- RNXT 35.37
- Support Level
- SHOT $0.46
- RNXT $1.00
- Resistance Level
- SHOT $0.51
- RNXT $1.18
- Average True Range (ATR)
- SHOT 0.04
- RNXT 0.10
- MACD
- SHOT 0.01
- RNXT -0.03
- Stochastic Oscillator
- SHOT 0.06
- RNXT 6.00
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.